Charles Michaud
Nessuna posizione attualmente
Patrimonio netto: 26 178 $ in data 30/04/2024
Profilo
Charles Michaud worked as a Controller at AOBiome Therapeutics, Inc. from 2019 to 2020.
He then held the position of Vice President-Finance & Controller at Homology Medicines, Inc. in 2023.
Mr. Michaud holds an MBA from Boston University and an undergraduate degree from the University of Massachusetts.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
0.01% | 25/03/2024 | 927 ( 0.01% ) | 26 178 $ | 30/04/2024 |
Precedenti posizioni note di Charles Michaud
Società | Posizione | Fine |
---|---|---|
AOBiome Therapeutics, Inc.
AOBiome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA. | Comptroller/Controller/Auditor | 01/06/2020 |
Q32 BIO INC. | Direttore Finanziario/CFO | - |
Formazione di Charles Michaud
University of Massachusetts | Undergraduate Degree |
Boston University | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 2 |
---|---|
Homology Medicines, Inc.
Homology Medicines, Inc. Pharmaceuticals: MajorHealth Technology Homology Medicines, Inc. is a clinical-stage genetic medicines company, which engages in the translation of proprietary gene editing and gene therapy technology into novel treatments for patients with rare genetic diseases. The company was founded in March 2015 and is headquartered in Bedford, MA. | Health Technology |
AOBiome Therapeutics, Inc.
AOBiome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Charles Michaud